Africa: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Africa: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Statement on the Efficacy of the AstraZeneca COVID-19 Vaccine (ChAdOx1 nCoV-19) against the SARS-CoV-2 Variants
10 February 2021
Dr Nicaise Ndembi, Senior Science Advisor, Africa CDC
[Excerpt]
Africa CDC recommendations to Member States and health authorities
On the 9 February 2021, Africa CDC convened a special session of the Africa Task Force for COVID-19 to review existing data and evidence and recommend the following:
[1] For countries that have NOT reported the circulation of the SARS-CoV-2 N501Y.V2 (or B.1.351), we recommend proceeding with the rollout of the AstraZeneca vaccine.
[2] For countries that HAVE reported the circulation of the SARS-CoV-2 N501Y.V2 (or B.1.351), we recommend the acceleration of their preparedness to introduce all COVID-19 vaccines that have received emergency use authorization or approval by regulatory authorities. Consideration should be given to the effectiveness of the vaccine against SARS-CoV-2 N501Y.V2 or any other circulating SARS-CoV-2 variant in the country.
[3] All countries should expand their genomic surveillance testing capacity, or liaise with the Africa CDC/WHO continental COVID-19 genome sequencing laboratory network. The Africa CDC Pathogen Genomics Initiative aims to enhance disease surveillance on the continent.
[4] All countries should strengthen their clinical trials research capacity to generate data on the safety and efficacy of vaccine candidates in African populations as recommended by the Africa CDC Consortium for COVID-19 Vaccine Clinical Trials (CONCVACT).